ACRV · Acrivon Therapeutics, Inc.

$2.06 -0.09 (-4.19%) At close · Aug 28

Market Cap

$88.28M

42.85M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income

-$77.91M +3.3%

FY2025

Diluted EPS

-$2.02 +15.1%

FY2025

Operating Cash Flow

-$63.67M +3.1%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Research & Development	+35.8%	—	—	$57.4M	$59.99M	$63.99M	$46.02M	$23.95M	—
General & Administrative	+40.4%	—	—	$20.97M	$24.12M	$25.21M	$21.08M	$8.71M	—
Total Operating Expenses	+37.1%	—	—	$78.37M	$84.11M	$89.2M	$67.1M	$32.66M	$16.18M
Operating Income	—	—	—	-$78.37M	-$84.11M	-$89.2M	-$67.1M	-$32.66M	-$16.18M
Interest Income	—	—	—	—	—	—	$7M	$1.5M	—
Other Non-Operating Income	+60.9%	—	—	$4.15M	$6.21M	$8.64M	$6.72M	$1.49M	-$59K
Pretax Income	—	—	—	—	-$77.83M	-$80.44M	—	—	—
Income Tax	—	—	—	—	$0	—	—	—	—
Net Income	—	—	—	-$74.23M	-$77.91M	-$80.56M	-$60.39M	-$31.17M	-$16.24M
Comprehensive Income	—	—	—	-$74.36M	-$78.24M	-$80.03M	-$60.38M	-$31.26M	—
EPS (Basic) USD/shares	—	—	—	-$1.88	-$2.02	-$2.38	-$2.74	-$7.56	-$9.32
EPS (Diluted) USD/shares	—	—	—	-$1.88	-$2.02	-$2.38	-$2.74	-$7.56	-$9.32
Shares Outstanding (Basic Avg) shares	+110.6%	—	—	—	38.51M	33.79M	22.08M	4.12M	1.74M
Shares Outstanding (Diluted Avg) shares	+110.6%	—	—	—	38.51M	33.79M	22.08M	4.12M	1.74M

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 4.60×

EV/EBIT

—

Peer median 11.01×

P/E (TTM)

—

Peer median 9.64×

Peer medians compare against the 294 similar-size Biotechnology companies (of 524 listed).

Key facts CIK 1781174 CUSIP 004890109 13F (30d) 44 filings 44 filers Visit website Investor relations